肿瘤NGS企业世和基因科创板IPO申请获受理 已连续三年盈利

智通财经
Jun 29
【肿瘤NGS企业世和基因科创板IPO申请获受理 已连续三年盈利】上交所官网显示,南京世和基因生物技术股份有限公司科创板IPO申请获受理,拟募资17亿元。招股书显示,世和基因主要面向肿瘤精准医疗领域提供相关分子诊断产品及服务,公司2023年-2025年分别实现营收5.72亿元、4.96亿元和5.77亿元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10